These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 21420886)
1. Utility of cytokeratin 5/6 and high-molecular-weight keratin in evaluation of cauterized surgical margins in excised specimens of breast ductal carcinoma in situ. Nayak A; Bhuiya TA Ann Diagn Pathol; 2011 Aug; 15(4):243-9. PubMed ID: 21420886 [TBL] [Abstract][Full Text] [Related]
2. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ. Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506 [TBL] [Abstract][Full Text] [Related]
3. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ. Martinez AP; Cohen C; Hanley KZ; Li XB Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088 [TBL] [Abstract][Full Text] [Related]
4. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Rabban JT; Koerner FC; Lerwill MF Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976 [TBL] [Abstract][Full Text] [Related]
5. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy. Grin A; O'Malley FP; Mulligan AM Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450 [TBL] [Abstract][Full Text] [Related]
6. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience. Sahoo S; Recant WM; Jaskowiak N; Tong L; Heimann R Breast J; 2005; 11(4):242-7. PubMed ID: 15982389 [TBL] [Abstract][Full Text] [Related]
7. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast]. Niu F; Wang L; Zhang W; Lyu S; Niu Y Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593 [TBL] [Abstract][Full Text] [Related]
8. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast. Macdonald HR; Silverstein MJ; Lee LA; Ye W; Sanghavi P; Holmes DR; Silberman H; Lagios M Am J Surg; 2006 Oct; 192(4):420-2. PubMed ID: 16978941 [TBL] [Abstract][Full Text] [Related]
9. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Steinman S; Wang J; Bourne P; Yang Q; Tang P Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367 [TBL] [Abstract][Full Text] [Related]
10. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins. Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190 [TBL] [Abstract][Full Text] [Related]
11. Optimal use of re-excision in patients diagnosed with early-stage breast cancer by excisional biopsy treated with breast-conserving therapy. Caughran JL; Vicini FA; Kestin LL; Dekhne NS; Benitez PR; Goldstein NS Ann Surg Oncol; 2009 Nov; 16(11):3020-7. PubMed ID: 19636632 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA Breast J; 2009; 15(2):120-32. PubMed ID: 19292797 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of 14-3-3 sigma and related proteins in hyperplastic and neoplastic breast lesions, with particular reference to early carcinogenesis. Simooka H; Oyama T; Sano T; Horiguchi J; Nakajima T Pathol Int; 2004 Aug; 54(8):595-602. PubMed ID: 15260850 [TBL] [Abstract][Full Text] [Related]
14. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor. Xu S; Wei B; Zhang H; Qing M; Bu H Oncol Rep; 2008 Jun; 19(6):1469-75. PubMed ID: 18497952 [TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334 [TBL] [Abstract][Full Text] [Related]
16. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968 [TBL] [Abstract][Full Text] [Related]
17. The effect of margins on the clinical management of ductal carcinoma in situ of the breast. Meijnen P; Gilhuijs KG; Rutgers EJ J Surg Oncol; 2008 Dec; 98(8):579-84. PubMed ID: 19072848 [TBL] [Abstract][Full Text] [Related]
18. Extent and histologic pattern of atypical ductal hyperplasia present on core needle biopsy specimens of the breast can predict ductal carcinoma in situ in subsequent excision. Wagoner MJ; Laronga C; Acs G Am J Clin Pathol; 2009 Jan; 131(1):112-21. PubMed ID: 19095574 [TBL] [Abstract][Full Text] [Related]
19. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232 [TBL] [Abstract][Full Text] [Related]
20. Factors affecting successful breast conservation for ductal carcinoma in situ. Dillon MF; Mc Dermott EW; O'Doherty A; Quinn CM; Hill AD; O'Higgins N Ann Surg Oncol; 2007 May; 14(5):1618-28. PubMed ID: 17443388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]